跳至主要内容
临床试验/CTRI/2025/03/083289
CTRI/2025/03/083289尚未招募3 期

A Single-center, Investigator-blinded, Randomized, 24-month, Parallel-group, Non-inferiority Study to Compare the Efficacy of Combination of Ayurvedic Therapy as Add-on treatment Versus Standard treatment in Oral Pre-malignant Lesions and Early Oral Cancer

ICMR & MINISTRY OF AYUSH1 个研究点 分布在 1 个国家目标入组 338 人开始时间: 2025年9月1日最近更新:

试验速览

阶段
3 期
状态
尚未招募
发起方
入组人数
338
试验地点
1
主要终点
1. Ki67 index and Biological Markers (COX2, P53) in Oral Lesion

研究概览

简要总结

(i)             Rationale -Medical and Surgical Interventions for premalignant lesions such as Leukoplakia, Erythroplakia and Oral submucous fibrosis have limited success. Few studies have explored the usefulness of Ayurveda medications in cancer. Newer drugs and targeted therapy to be explored to address this pressing problem in India.

(ii)           Novelty – The study is being planned to integrate traditional medicine with modern medicine for a common disease in India, with the aim to find an alternative method to meet the urgent need of the vulnerable population.

·      Objectives – To evaluate the effect of Ayurveda treatment on cell proliferation (Ki67) and  molecular targets (COX2, P53) in the target lesion in Oral Cancer.

·      To monitor the effect of Ayurveda treatment on symptom score (measured by Visual Analogue Scale) among the study groups at pre and post intervention

·      To evaluate the effect of Ayurveda treatment on mouth opening in Oral Submucous fibrosis.

·      To evaluate the effect of Ayurveda treatment on the appearance and size of  lesions with leukoplakia and erythroplakia.

 (iii)         Methods –

Study Design - This study will adopt a Randomized Controlled Assessor-Blinded Trial

Study Duration – 2 years

 Sample Size – The sample size estimated in each subgroup using Openepi v3.1 and G*Power software. The estimates are given below.

 Subgroup 1 - Premalignant Group– 86 in each group (Total N= 172)

Subgroup 2 – Submucous Fibrosis – 50 in each group (Total N= 100)

Subgroup 3 – Early Oral cancer– 33 in each group (Total N= 66)

 Study population –

The patients visiting the outpatient department with oral premalignant lesions and oral cancer will be prospectively enrolled in the study.

Recruitment and Participants –

·      After getting permission from the Institutional Ethics Committee, patients with oral premalignant and malignant lesions, will be recruited from ENT OPD after obtaining informed consent.

·      The patients will be grouped into two categories;

a) Receiving Standard Treatment - Betel Nut/Areca Nut/Quid and Tobacco cessation, Dietary Modification  for 3 months

b) Standard Treatment along with Ayurvedic treatment as add on therapy for 3 months

 (iv)          Expected outcome - The aim of this study is to develop a rationale for prevention of oral cancer from premalignant lesions by using traditional medicine and to generate evidence for the treatment of these lesions by Ayurveda drugs.

研究设计

研究类型
Interventional
分配方式
Randomized
盲法
Outcome Assessor Blinded

入排标准

年龄范围
18.00 Year(s) 至 60.00 Year(s)(—)
性别
All

入选标准

  • Patients with clinical characteristic of pre-malignant lesions including Leukoplakia and Erythroplakia whose diagnosis will be confirmed with histology.
  • Patients with clinical characteristic of Oral Submucous Fibrosis (OSMF).
  • Patients with Oral Squamous Cell Carcinoma (OSCC) with lesion less than 2 cm in size cT1
  • Patients with Carcinoma in situ and dysplasia on histopathology
  • No evidence of cervical lymph node metastasis and distant metastasis.
  • No history of prior treatment for the same.
  • Patients who have quit the habit and accepted for regular follow up.
  • Patients having a mouth opening, ranging from 15-35 mm will be included in the study.

排除标准

  • Patients not willing to give consent for participation.
  • Patients with locally advanced Oral squamous cell carcinoma
  • Patients with Oral Lichen Planus
  • Patients with cardiac, respiratory, renal, and hepatic diseases.
  • Pregnant women and lactating mothers.
  • Patients with Autoimmune diseases
  • Patients with severe Trismus with mouth opening less than 15 mm
  • Patients with HIV and those who are Immunocompromised
  • Patients with hypersensitivity to Ayurveda drugs.

结局指标

主要结局

1. Ki67 index and Biological Markers (COX2, P53) in Oral Lesion

时间窗: 1. Clinical assessment on Day 30, Day 60, Day 90, Day 120, Day 150 and Day 180 | 2. Ki67 index and Biological Markers (COX2, P53) on Day 0, Day 30(Oral Cancer) and Day 60 (Premalignant lesion)

2. change in symptom score (measured by Visual Analogue Scale) and Mouth opening (measured by Inter-incisal distance) in patients with Oral Submucous fibrosis

时间窗: 1. Clinical assessment on Day 30, Day 60, Day 90, Day 120, Day 150 and Day 180 | 2. Ki67 index and Biological Markers (COX2, P53) on Day 0, Day 30(Oral Cancer) and Day 60 (Premalignant lesion)

3. clinical response (assessed by change in appearance on clinical photographs) and change in size (measured by geometric scale in 2 dimensions) among the oral lesions

时间窗: 1. Clinical assessment on Day 30, Day 60, Day 90, Day 120, Day 150 and Day 180 | 2. Ki67 index and Biological Markers (COX2, P53) on Day 0, Day 30(Oral Cancer) and Day 60 (Premalignant lesion)

次要结局

  • 1. Change in histopathology (assessed by histopathology/cytology) in the target lesion(2. QoL (measured by change in EORTC QLQ – H&N43 score) among the study groups)

研究者

发起方
ICMR & MINISTRY OF AYUSH
申办方类型
Government funding agency
责任方
Principal Investigator
主要研究者

Kiran Kumar Prathipati

All India Institute of Medical Sciences Nagpur

研究点 (1)

Loading locations...

相似试验